OCTOBER 10, 2018 As published in Genome Web’s 360Dx NEW YORK, NY – BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a laboratory-developed test used for the diagnosis of early-stage lung cancer. BioAffinity President and CEO […]
OCTOBER 10, 2018 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies, a San Antonio-based biotech, has struck a deal with another local company, Precision Pathology Services, to sell its CyPath Lung device nationally. The arrangement furthers bioAffinity’s progress toward making its market debut with the […]
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San Antonio-based firm anticipates that its CyPath Lung diagnostic assay will be available […]
JULY 19, 2018 As published in the San Antonio Business Journal By W. Scott Bailey Roughly four years after its San Antonio launch, cancer diagnostics company bioAffinity Technologies is only months away from taking its initial product — CyPath Lung — to market. The privately held biotech has started a validation trial for the product, […]
MAY 15, 2018 As published in Xconomy Texas By David Holley (SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of raising a $5 million […]
MARCH 1, 2018 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio-based bioAffinity Technologies has been approved for membership in the Early Detection Research Network, an initiative of the National Cancer Institute. The approval gives the privately held biotech – which is advancing the commercialization of its first product, a lung […]